Trial Profile

A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 18 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aficamten (Primary)
Indications Hypertrophic cardiomyopathy
Focus Adverse reactions
Acronyms FOREST-HCM; FOREST-HCM CMR; REDWOOD-HCM OLE
Sponsors Cytokinetics

Most Recent Events

29 Sep 2025 Results presented in the Cytokinetics media release
31 Aug 2025 According to a Cytokinetics media release, data from this study published in Heart Rhythm.
07 Aug 2025 According to a Cytokinetics media release, 48-weeks Results From the study were presented in the Journal of the American College of Cardiology Heart Failure

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com